Neuromyelitis optica (NMOSD): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• AQP4 11
• CD20 4
• CD19 6
• BCMA 8
• IL-6 0
• STAT3 0
• STING 0
• TIM-3 0
• APOE 0
• BTK 0
• FOXP3 0
• IGF1R 0
• IL-1 0
• PD-1 0
• PD-L1 0
• PI3K 0
• PPAR 0
• TIGIT 0
• YAP 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 451 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

  NCT07247292· AstraZeneca· Updated 21 Jul 2026

  “The decision is based on strategic deprioritization and is not related to any safety concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

  NCT06869278· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Updated 24 Jun 2026

  “Legend discontinues the development of the IMP.”Registry text, quoted unchanged. Source

• Terminated

  An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

  NCT05356858· Xuanwu Hospital, Beijing· Updated 27 Apr 2026

  “Difficult in participant recruiting”Registry text, quoted unchanged. Source

• Terminated

  A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

  NCT03330418· RemeGen Co., Ltd.· Updated 13 Apr 2026

  “Sponsor Strategic Priority Adjustment”Registry text, quoted unchanged. Source

• Withdrawn

  Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder

  NCT06673394· Tianjin Medical University General Hospital· Updated 10 Sept 2025

  “The study plan need to be modified after widely discussion with our consultation board, regarding the conscern about the efficiency may not be able to detect the expected differences. We would like to withdraw this study plan and startup a new one.”Registry text, quoted unchanged. Source

• Withdrawn

  A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

  NCT05974293· Michael, Levy M.D.,Ph.D.· Updated 16 Jul 2025

  “Funding was withdrawn.”Registry text, quoted unchanged. Source

• Withdrawn

  Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders

  NCT05909943· Tianjin Medical University General Hospital· Updated 18 Jun 2023

  “We are doing a clinical study of Baritinib in Neuromyelitis Optica Spectrum Disorders, similar to this one, so the study was withdrawn.”Registry text, quoted unchanged. Source

• Withdrawn

  MS and NMOSD in African-Americans

  NCT04131673· Jagannadha R Avasarala· Updated 14 Nov 2022

  “IRB closed”Registry text, quoted unchanged. Source

• Withdrawn

  Autologous Transplant To End NMO Spectrum Disorder

  NCT03829566· Northwestern University· Updated 20 Nov 2019

  “Discontinued by Investigator”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

  NCT05909761· Amgen· Source

• Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

  NCT05966467· Alexion Pharmaceuticals, Inc.· Source

• A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

  NCT05199688· Hoffmann-La Roche· Source

• Clinical study testing the efficacy and safety of Ravulizumab in pediatric patients with NMOSD

  2023-508534-33-00· Alexion Pharmaceuticals Inc.· Source

• Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

  NCT07557420· Alexion Pharmaceuticals, Inc.· Source

• A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD

  NCT07762872· Junwei Hao, MD· Source

• Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

  NCT07247292· AstraZeneca· Source

• Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

  NCT05346354· Alexion Pharmaceuticals, Inc.· Source

• lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder

  2024-517176-38-00· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

  NCT05982925· Icahn School of Medicine at Mount Sinai· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 5
• Gene Expression Profiling 1
• Proteomics 3
• Metabolomics 2
• Flow Cytometry 2
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 80
• Machine Learning 3
• Deep Learning 1
• Cohort Studies 22
• Genome-Wide Association Study 2

• Microstructure-informed deep learning improves thalamic atrophy segmentation and clinical associations in multiple sclerosis and related neuroimmunological diseases.

  Neuroimage Clin, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.